Pulmonary embolism

194,122views

Pulmonary embolism

Joana

Joana

Mycobacterium tuberculosis (Tuberculosis)
Tuberculosis: Pathology review
Diabetes insipidus
Diabetes mellitus
Hypoglycemics: Insulin secretagogues
Thyroid cancer
Thyroid nodules and thyroid cancer: Clinical
Diabetes mellitus: Clinical
Hypertriglyceridemia
Anatomy of the thyroid and parathyroid glands
Insulins
Diabetes mellitus
Adrenal masses: Pathology review
Adrenal masses and tumors: Clinical
Adrenal insufficiency: Pathology review
Primary adrenal insufficiency
Congenital adrenal hyperplasia
Adrenal gland histology
Adrenal masses: Pathology review
Adrenal masses and tumors: Clinical
Esophageal cancer
Gastric cancer
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Peptic ulcers and stomach cancer: Clinical
Colorectal cancer
Colorectal cancer: Clinical
Metaplasia and dysplasia
Diabetic nephropathy
Benign liver tumors
Hepatocellular carcinoma
Peptic ulcer
Peptic ulcer
Helicobacter pylori
Cirrhosis
Inflammatory bowel disease: Pathology review
Inflammatory bowel disease: Clinical
Gallbladder carcinoma
Wilson disease
Pancreatic cancer
Carcinoid syndrome
Acromegaly
Viral hepatitis
Hyperthyroidism: Clinical
Alcohol-associated liver disease
Non-alcoholic fatty liver disease
Pituitary adenoma
Non-steroidal anti-inflammatory drugs
Diarrhea: Clinical
Metabolic acidosis
Metabolic alkalosis
Ulcerative colitis
Crohn disease
Respiratory acidosis
Nephrotic syndromes: Pathology review
Goodpasture syndrome
Nephritic syndromes: Pathology review
Respiratory alkalosis
Cholestatic liver disease
Laxatives and cathartics
Polycystic ovary syndrome
MEN syndromes: Clinical
Autoimmune polyglandular syndrome type 1 (NORD)
Type I and type II errors
Gastroesophageal reflux disease (GERD)
Celiac disease
Polycystic kidney disease
Chronic kidney disease
Acute kidney injury: Clinical
IgA nephropathy (NORD)
Focal segmental glomerulosclerosis (NORD)
Minimal change disease
Chronic kidney disease: Clinical
Cytomegalovirus infection after transplant (NORD)
Hyperkalemia: Clinical
Atherosclerosis and arteriosclerosis: Pathology review
Portal hypertension
Cirrhosis: Clinical
Hypercholesterolemia: Clinical
Gallbladder histology
Chronic cholecystitis
Gout
Gout and pseudogout: Pathology review
Lesch-Nyhan syndrome
Macrocytic anemia: Pathology review
Alpha-thalassemia
Beta-thalassemia
Anemia: Clinical
Sickle cell disease (NORD)
Sickle cell disease: Clinical
Aplastic anemia
Von Willebrand disease
Acute leukemia
Lung cancer: Clinical
Lung cancer
Breast cancer: Clinical
Breast cancer
Monoclonal antibodies
Atrioventricular block
Heart blocks: Pathology review
Abnormal heart sounds
Heart failure
Pulmonary embolism
Pulmonary edema
Pulmonary valve disease
Cell-mediated immunity of CD4 cells
Cell-mediated immunity of natural killer and CD8 cells
Innate immune system
Introduction to the immune system
Complement system
T-cell development
B-cell development
MHC class I and MHC class II molecules
T-cell activation
B-cell activation, differentiation, and contraction
Antibody classes
Somatic hypermutation and affinity maturation
VDJ rearrangement
Contracting the immune response and peripheral tolerance
B- and T-cell memory
Vaccinations
Type I hypersensitivity
Food allergy
Anaphylaxis
Asthma
Type II hypersensitivity
Type III hypersensitivity
Type IV hypersensitivity
Graft-versus-host disease
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
ELISA (Enzyme-linked immunosorbent assay)
Gel electrophoresis and genetic testing
Fluorescence in situ hybridization
Precipitation reactions
Isolated primary immunoglobulin M deficiency
Selective immunoglobulin A deficiency
Blood groups and transfusions
Systemic lupus erythematosus
Systemic lupus erythematosus (SLE): Pathology review
Systemic lupus erythematosus (SLE): Clinical
Chronic granulomatous disease
Complement deficiency
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review
DiGeorge syndrome
X-linked agammaglobulinemia
Hyper IgM syndrome
Leukocyte adhesion deficiency
Immunodeficiencies: Clinical
HIV (AIDS)
Cell-cell junctions
Hashimoto thyroiditis
Wiskott-Aldrich syndrome
Food allergies and EpiPens: Information for patients and families (The Primary School)
Vaccinations: Clinical
Blood products and transfusion: Clinical
Hypersensitivity skin reactions: Clinical
Shock: Clinical
Rheumatic heart disease
Immune thrombocytopenia
Rheumatoid arthritis
Rheumatoid arthritis: Clinical
Multiple sclerosis

Transcript

Watch video only

A pulmonary embolism happens when an embolus, which is a type of blockage, suddenly gets lodged inside a pulmonary artery.

Depending on which pulmonary artery or arteries are affected by the blockage, that can seriously decrease the amount of oxygenated blood that gets out to the body.

Normally, blood makes it back to the heart from all of the tissues and organs through a network of veins that merge over and over.

Superficial veins drain blood into deep veins, which rely on the skeletal muscle pump to move blood forward. The way it works is that the surrounding skeletal muscles compress the vein and propel blood forward, and the veins prevent blood from moving backwards by using one-way valves.

Ultimately, all of the blood ends up in the superior or inferior vena cava and dumps into the right atrium.

From there the blood goes into the right ventricle and gets pumped into pulmonary artery and eventually into the lungs.

The pulmonary artery splits at a spot called the pulmonary saddle, which looks like a bit like a horse saddle, and then the right and left pulmonary arteries enter their respective lungs.

Subsequent branches off the pulmonary artery lead to smaller and smaller arteries, then arterioles, and finally capillaries that form nets around the alveoli, which is where gas exchange occurs.

When a pulmonary embolism happens, a blockage in any of the arteries leads to a decrease in blood flow to lung tissue downstream.

The majority of the time, this blockage is caused by a broken off piece of a blood clot commonly associated with deep vein thrombosis.

A deep vein thrombosis most commonly develops in the lower legs, below the knee, although a blood clot can form in both superficial and deep veins and also in other parts of the body as well.

Normally, the process starts with damage to the endothelium, or inner lining of blood vessel walls, after which there’s an immediate vasoconstriction or narrowing of the blood vessel which limits the amount of blood flow.

After that, some platelets adhere to the damaged vessel wall, and become activated by collagen and tissue factor, which are proteins that are normally kept separated from the blood by an intact endothelium.

These platelets then recruit additional platelets to form a platelet plug. This formation of the platelet plug is called primary hemostasis.

After that, the coagulation cascade is activated.

First off in the blood there’s a set of clotting factors, most of which are proteins synthesized by the liver, and usually these are inactive and just floating around in the blood.

The coagulation cascade starts when one of these proteins gets proteolytically cleaved.

This active protein then proteolytically cleaves and activates the next clotting factor, and so on.

The final step is activation of the protein fibrinogen to fibrin, which deposits and polymerizes to form a mesh around the platelets.

So these steps leading up to fibrin reinforcement of the platelet plug make up the process called secondary hemostasis and results in a hard clot at the site of the injury.

This cascade has a huge degree of amplification and takes only a few minutes from injury to clot formation.

So the activation of the cascade is carefully controlled by anticoagulation proteins that target and inactivate key clotting factors.

For example, antithrombin inactivates Factors IXa, Xa, XIa, XIIa, VIIa and thrombin while protein C inactivates Factors Va and VIIIa.

As the clot grows in size, it limits the amount of blood able to pass by, and pressure in the vein increases.

Usually the clot might start naturally breaking down, for example, enzymes like plasmin break down fibrin into fragments called D-dimers.

But sometimes, the increased pressure in the vein can cause a part of the main clot to break free, becoming a thromboembolus which can travel downstream towards the heart.

When that happens, a thromboemobolus - which is a blood clot on the move - can move from the spot of clot formation and get into the right atrium, and then into the right ventricle and get pumped into the lungs where it can get lodged some place - causing a pulmonary thromboembolism. This is a life-threatening situation because it literally blocks blood from getting into the lungs to pick up oxygen.

If there’s no blood flowing past an alveoli, then that means there are alveoli that are getting ventilated with fresh air but not getting perfused with blood. We call this a ventilation perfusion mismatch or a V/Q mismatch.

The body needs oxygenated blood to function and can therefore only tolerate a bit of a V/Q mismatch, before the lungs are no longer able to meet the needs of the body.

The amount of V/Q mismatch ultimately depends on the number, size, and location of the pulmonary thromboembolisms, which tells us the amount of lung tissue that’s being denied blood flow.

A physiologic response to all of this is hyperventilation.

Key Takeaways

Pulmonary embolism (PE) is a blockage of the lungs main artery or one of its branches by a substance that has traveled from elsewhere in the body through the bloodstream (embolism). PE most commonly results from a deep vein thrombosis (commonly a blood clot in a leg) that breaks off and migrates to the lung, a process termed venous thromboembolism (VTE). This can cause serious damage to the lung tissue and can be life-threatening.

Symptoms vary by the amount of downstream lung tissue denied blood, which creates a ventilation-perfusion mismatch. They include shortness of breath, chest pain, and coughing. PE can also cause low blood oxygen levels, which can lead to confusion, loss of consciousness, and even death. Treatment of PE typically involves supportive therapy and blood thinning medications to dissolve the clot and prevent further clots from forming. Sometimes a filter is placed in the vena cava to trap clots before they reach the lungs.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  5. "Thrombosis" Arteriosclerosis, Thrombosis, and Vascular Biology (2014)
  6. "Acute pulmonary embolism: An update on diagnosis and management" Current Problems in Cardiology (2005)
  7. "Epidemiology, Pathophysiology, and Natural History of Pulmonary Embolism" Seminars in Interventional Radiology (2018)